Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative...

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) patients on infliximab may lose response over time.
• Ulcerative colitis (UC) patients often require infliximab dose adjustments.
• Limited data exists on infliximab dose optimization strategies for UC.

Purpose of the Study:

• To evaluate infliximab dose optimization in ulcerative colitis patients experiencing secondary loss of response.
• To compare the efficacy of doubling the infliximab dose versus shortening the dosing interval.

Main Methods:

• Retrospective multicenter study involving 41 ulcerative colitis patients.
• Assessed rapid clinical response post-dose intensification.
• Compared doubling the dose (10mg/kg q8 weeks) versus shortening the interval (5mg/kg every 6 or 4 weeks).

Main Results:

• 90.2% achieved rapid clinical response; 46.3% achieved rapid clinical remission.
• At 52 weeks, 28/41 patients maintained remission; 4 (9.8%) required colectomy.
• No significant difference between dose optimization strategies; rapid response correlated with higher colectomy-free rates (p=0.002).

Conclusions:

• Infliximab dose optimization is effective for restoring response and remission in UC patients with secondary loss of response.
• Dose optimization strategies can help prevent colectomy in ulcerative colitis.
• Both dose doubling and interval shortening are viable options for infliximab dose optimization in UC.